CAR T Cell Therapy Market is expected to grow with a CAGR of almost 50% in future.
30 Aug, 2018

 Get Free Customization in This Report 

Renub Research recent report on CAR T Cell Therapy Market, anticipate that it will grow at with a CAGR of almost 50% over the period of 2018-2028. Over some years, immunotherapy has emerged as one of the most curative ways in the treatment of cancerous tumors among the cancer community which strengthen the power of patient’s immune system to fight these tumors. Immunotherapy; adoptive cell transfer (ACT) for cancer treatment is evolving very rapidly adoptive cell transfer (ACT) which includes collection and usage of patient’s own immune cells in the treatment of their cancer. There are various types of adoptive cell transfer (ACT) are being developed namely; TILs, TCRs, and CARs, of which, CARs- CAR T-cell therapy is the only clinical developed advanced approach used in the treatment of cancer.

Request a free sample copy of the report: https://www.renub.com/contactus.php

Over the several years; the surgery, chemotherapy and radiation therapy are considered to be the best available treatment for cancer. Later, targeted therapies such as trastuzumab (Herceptin®) and imatinib (Gleevec®) like drugs which specifically targets cancer cells are being used in the cancer treatment.

CAR T Cell therapy is a treatment in which a patient’s immune system cell (T cell) are transformed in the clinical laboratory so that the transformed immune system cell will attack cancerous cell in the patient’s body. T cells are usually extracted from the patient’s blood, which is then treated in the laboratory with special receptor known as a chimeric antigen receptor (CAR) and hence, the treatment is termed as CAR T Cell Therapy. The chimeric antigen receptor (CAR) cells tend to act like an antigen on the cancer cells and kill them. Today, with the advancement in medical technology, a large number of CAR T cells are developed in the laboratory and is given to the cancer patients by infusion, which will certainly drive CAR T Cell Therapy Market to grow vigorously in the coming future with increasing cancer cases worldwide and the fuelling demand for better healthcare services from the consumer.

Recently, the Food and Drug Administration (FDA) has approved two CAR T-cell therapies in 2017 of which one is for the adults with advanced lymphomas and the other for the treatment of children with acute lymphoblastic leukemia (ALL). Nonetheless, the CAR T cells therapy and other forms of ACT are still in its early days and is still being developed and so, the researchers are still cautious about the CAR T cells therapy that will it ever be effective against solid tumors like breast and colorectal cancer.

Client can Purchase this Report in Sections from below link:

Access full Research:  https://www.renub.com/car-t-cell-therapy-market-p.php

With increasing research and development, the field of CAR T Cell therapy has reached a tipping point. In the recent years, development in the CAR T Cells and other ACT approaches has pushed immensely, as the researchers are developing a better understanding of how these therapies work with cancer patients and translating that outcome into improvements in how they are developed and tested more efficiently.

In the near future; it is believed that medical science will see a dramatic progress which will push all the boundaries that what a people thought was possible with these cell-transfer based treatments.

Key Topics Covered :

1.    Executive Summary

2.    Global Chimeric Antigen Receptor (CAR)-T cell Therapy Market

3.    Market Share – CAR-T Cell Therapy

3.1    By Geographical Region
3.2    By Targeted Antigens

4.    Targeted Antigen Market

4.1    CD19
4.2    CD20
4.3    GD2
4.4    CD22
4.5    CD30
4.6    CD33
4.7    HER2
4.8    Mesothelin (MESO)
4.9    EGFRvIII
4.10    Others

5.    Geographical CAR-T Cell Therapy Market (2016 -2026)

5.1    North America
5.2    Europe
5.3    Asia Pacific
5.4    Latin America
5.5    Middle East
5.6    Africa

6.    Global - CAR-T Cell Clinical Trials/Study

6.1    CD19
6.2    CD20
6.3    CD22
6.4    CD30
6.5    CD33
6.6    EGFRvIII
6.7    GD2
6.8    HER1
6.9    HER2
6.10    MESO

7.    China CAR-T Cells Clinical Trials Details

7.1    By Cities CAR-T Cells Clinical Trials
7.2    CD19 Directed CAR-T Cells Clinical Trials
7.3    Non-CD19 Directed CAR-T Cells Clinical Trials
7.4    Solid Tumors CAR-T Cells Clinical Trials

8.    CAR-T Cell Therapy SWOT Analysis

8.1    Strength
8.2    Weakness
8.3    Opportunities
8.4    Threats
 

9.    Regulation in CAR-T Cell Therapy

9.1    United States
9.2    European Union
9.3    China

10.    IPO/Investment/Funding/Partnership in CAR-T Cell Therapy Market

10.1    Venture Capital Investment
10.2    Initial Public Offerings of CAR-T Companies
10.3    CAR-T Companies Strategic Partnerships/Deals
10.4    Key CAR-T Technology Deals

11.    Growth Drivers

11.1    FDA Approvals of CAR-T Therapy
11.2    Dramatically Increasing Number of CAR-T Cell Trials Globally

12.    Challenges

12.1    Regulatory Challenges
12.2    Very Expensive CAR-T Therapy Treatment

13.    Novartis

13.1    Company Overview
13.2    Initiatives
13.3    Financial Insight

14.    Gilead Sciences (Kite Pharma)

14.1    Company Overview
14.2    Company Initiatives
14.3    Company Financial Insight

15.    Celgene Corporation (Juno Therapeutics)

15.1    Company Overview
15.2    Company Initiatives
15.3    Company Financial Insight

16.    Celyad

16.1    Company Overview
16.2    Company Initiatives
16.3    Financial Insight

About Us

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Contact Us

Renub Research

Phone: +1-678-302-0700

Email: info@renub.com

Website: www.renub.com   

Follow us on LinkedIn: www.linkedin.com/company/renub-research